01 November 1999
Effect of glutamic acid, aspartic acid, glycine and gamma amino butyric acid on the growth of human leukemia and melanoma cells in vitro
Harrison Boldizasr, Bela Szende, Ferenc TimarMed Sci Monit 1999; 5(6): BR1059-1064 :: ID: 502974
Abstract
K 562 human leukemia cells and HT 168 melanoma cells were cultured for 72 hours in Minimal Essential Medium (MEM) with or without asparagine. (AspNH2) and supplemented with 2.6 mmol/l glycine (Gly), 1.9 mmol/l gamma amino butyric acid (GABA), 1.5 mmol/l aspartic acid (Asp) or 6.8 mmol/l glutamic acid (Glu). Gly significantly inhibited the proliferation of both types of tumor cells both in the presence and the absence of AspNH2. This inhibitory effect developed gradually, usually by the 48th hour of incubation. Some of the Gly-treated cells showed signs indicative of apoptosis. In AspNH2-free MEM both the control and the experimental cell groups (supplemented with Gly, GABA, Asp or Glu) showed much slower proliferation than in MEM containing AspNH2. The values obtained in GABA-supplemented MEM in 72 hour experiment did not differ significantly from the control. Glu and Asp induced a significant rise in the growth of leukemia cells by the 3rd day of incubation. The growth of melanoma cells in Glu- or Asp-containing MEM did not significantly
differ from the control but significantly exceeded the value obtained in MEM supplemented with Gly. It is supposed that Cl-transport into tumor cells decreases and Na+ transport increases as a result of changes in the extracellular/intracellular ratio of excitatory/inhibitory amino acids. This results in depolarization which maintains cell division. The results suggest that some non-essential, transmitter amino acids exert either inhibitory or stimulating effect on tumor cell proliferation. This finding may open up new possibilities in preventing tumor growth.
Keywords: leukaemia and melanoma cells, transmitter amino acids, tumor cell proliferation
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952